Ceres,heisseste aktie 2016!
Seite 1 von 4 Neuester Beitrag: 25.04.21 03:36 | ||||
Eröffnet am: | 02.01.16 02:18 | von: iwanooze | Anzahl Beiträge: | 83 |
Neuester Beitrag: | 25.04.21 03:36 | von: Lisafytla | Leser gesamt: | 10.950 |
Forum: | Hot-Stocks | Leser heute: | 1 | |
Bewertet mit: | ||||
Seite: < 1 | 2 | 3 | 4 4 > |
http://www.ariva.de/vita_34-aktie/bilanz-guv
Profil
Vita 34 ist eine führende Nabelschnurblutbank in Europa. Sie bietet als Komplettanbieter die Entnahmelogistik, Aufbereitung und Einlagerung von Nabelschnurblut und Nabelschnurgewebe an. Bei der sogenanten Kryokonservierung werden Zellen und Gewebe bei Temperaturen um minus 190 Grad Celsius am Leben erhalten und können bei Bedarf im Rahmen einer medizinischen Therapie eingesetzt werden. Stammzellpräparate von Vita 34 werden zum Beispiel zur Behandlung von Patienten sowie im Rahmen der medizinischen Forschung zur Herzinfarkt- oder Schlaganfalltherapie eingesetzt. Daneben bietet die Firma kostenpflichtige Vorsorge-Screenings zur Früherkennung von genetisch bedingten Gesundheitsrisiken bei Kindern an. Erkannt werden können Erkrankungen wie Laktose- und Gluten-Intoleranz, Antibiotika-Unverträglichkeit oder Hämochromatose (Eisenspeicherkrankheit).
Copyright 2014 FINANCE BASE AG
und ich bin ein bekennender Ossi.
Was hat das jetzt damit zu tun.
Kennst du Leipzig?
http://www.leipzig.de/wirtschaft-und-wissenschaft/...fil-und-cluster/
Wirtschaftsprofil und Cluster
Automobil- und Zulieferindustrie
Gesundheitswirtschaft und Biotechnologie
Energie und Umwelttechnik
Logistik
Medien- und Kreativwirtschaft
http://www.streetinsider.com/Corporate+News//...%246.7M/11153728.html
Ein insgesamt 600.000 Stammaktien, 6460 Aktien von Vorzugsaktien wandelbar in 16.150.000 Aktien der Stammaktien, Bezugsrecht auf 16.750.000 Aktien der Stammaktien werden im Rahmen des Angebots erteilt werden.
Nix gegen heron, seine wertfreien Einschätzungen bei aezs haben mir ordentliche gewinne beschert. Aber eine Aktie kaufen um der Menschheit was gutes zu tun ist Heuchelei da kann man doch besser nach nem spendenkonto fragen, bekommt dann ne Quittung die man steuerlich geltend machen kann und hat nicht den stress wenn der Kurs fällt.
Genzeug ist für mich nur die logische Fortführung eines ausgehebelt en Darwinismus. Einfach mal heuristisch betrachten.
Jedenfalls werd ich die Aktie weiter beobachten aber vor der verwässern wohl eher noch einsteigen.
https://translate.google.at/...ference-300195532.html&prev=search
hier original
http://investor.ceres.net/releasedetail.cfm?ReleaseID=947742
PERSEPHONE
http://ceres.net/?page_id=48
wird vorgestellt auf der conference zwischen 9 und 13 .1.2016
http://www.intlpag.org/
http://finance.yahoo.com/news/ceres-announces-first-quarter-financial-210500138.html
Ceres Announces First Quarter Financial Results of Fiscal Year 2016
- Company confirms its savings target; plans to achieve $8 to $10 million in cash savings in FY2016 versus original estimate of $6 to $8 million.
- Completes shift away from bioenergy into higher value forage and feed crops.
- Key field performance results will be announced in coming weeks.
PR Newswire
THOUSAND OAKS, Calif., Jan. 14, 2016 /PRNewswire/ -- Ceres, Inc. (CERE), an agricultural biotechnology company focused on forage crops, today reported financial results for the three months ended November 30, 2015 and provided an update on its business.
During its fiscal first quarter, Ceres continued to refocus its business on commercializing forage products with a better balance of yield, energy and nutrition. The company also significantly strengthened its balance sheet, successfully completing a $7.6 million equity offering, and further validated its technology in forage crops via a multi-year collaboration with Forage Genetics International, a leading developer, producer and marketer of alfalfa breeding lines and traits.
For the upcoming planting season, Ceres plans to increase the number of companies distributing its forage sorghum seeds, expand its product portfolio and extend field evaluations of its seed products to additional regions. The company will announce key 2015 field results in coming weeks, including summaries of commercial forage sorghum plantings and pre-commercial hybrid and trait trials.
Ceres President and CEO Richard Hamilton said that the company plans to continue to make progress across its strategic initiatives in 2016. "Following our technical and commercial achievements in 2015, we successfully raised new funds to continue to build our forage sorghum seed business, advance our traits toward commercialization and demonstrate a clear trajectory for growth," he said.
"We look forward to continuing to deliver on our milestones, which begins with achieving our product development objectives. We expect success here to translate into additional distribution agreements and increased seed sales," Hamilton said.
Paul Kuc, Ceres Chief Financial Officer, indicated that previously announced cuts are expected to reduce operating expenses by $8 to $10 million in fiscal year 2016, higher than management's original forecast of $6 to $8 million in savings. "We have identified significant opportunities to reduce operating expenses and are rapidly implementing our realignment plan," said Kuc. "On an operational basis, we have completed our shift into forages and away from bioenergy and Brazil, and we expect the reduced cash requirements of our forage and traits business model to be fully reflected in our operating expenses beginning in February."
First Quarter Financial Results
Total revenues increased by $0.5 million to $0.9 million for the quarter ended November 30, 2015 compared to the same period last year primarily due to the recognition of revenue following the completion of work under the company's software services agreements.
Total cost and operating expenses decreased by $1.6 million to $4.8 million for the quarter ended November 30, 2015 compared to the same period last year.
Cost of product sales increased by $0.5 million to $0.9 million for the quarter ended November 30, 2015 compared to the same period last year primarily due to increased seed production costs.
Research and development expenses decreased by $0.8 million to $1.7 million for the quarter ended November 30, 2015 compared to the same period last year primarily due to reduced personnel and related expenses.
Selling, general and administrative expenses decreased by $1.3 million to $2.1 million for the quarter ended November 30, 2015 compared to the same period last year. In the U.S., expenses decreased by $0.8 million primarily due to reduced personal and related expenses and reduced professional fees. In Brazil, expenses decreased by $0.5 million primarily due to reduced personnel and related expenses as a result of restructuring the company's Brazil operations.
For the quarter ended November 30, 2015, Ceres reported a net loss of $3.4 million, or $0.39 per common share, compared to a net loss of $6.0 million, or $0.96 per common share, for the quarter ended November 30, 2014.
At November 30, 2015, cash and cash equivalents totaled $3.4 million.
Conference Call and Webcast Information
Ceres has scheduled a conference call for 4:30 p.m. EST (1:30 p.m. PST) today to discuss its fiscal first quarter results and to provide an update on its business. To access the webcast of the conference call, go to investor.ceres.net. Audio of the teleconference is also available by dialing (877) 838-4153 (domestic) or +1(720) 545-0037 (international). The conference ID number is 24039004. An audio replay of the call will be available two hours after the conclusion of the live call, and remain available on the Ceres website for 30 days.
About Ceres
Ceres, Inc. is an agricultural biotechnology company that develops and markets seeds and traits to produce crops for animal feed, sugar and other markets. The company's advanced plant breeding and biotechnology technology platforms, which can increase crop productivity, improve quality, reduce crop inputs and improve cultivation on marginal land, have broad application across multiple crops, including food, feed, fiber and fuel crops. Ceres markets its seed products under its Blade brand. The company also licenses its biotech traits and technology, including its Persephone genome visualization software, to other life science companies and organizations.
mal gespannt was heut in usa geht!
http://finance.yahoo.com/...hb2&fr=uh3_finance_vert_gs&s=CERE